Pain is the body’s alarm system, but sometimes the alarm keeps ringing long after the toast has stopped burning. Acute pain usually protects an injured area while it heals. Chronic pain, commonly defined as pain lasting longer than three months, can become a health condition of its own, influenced by inflammation, nerve signaling, sleep, mood, movement, previous injury, and social stress.
Modern pain management includes over-the-counter drugs, prescription medications, rehabilitation, psychological therapies, injections, surgery, implanted devices, and complementary approaches. The good news is that patients have more choices than ever. The less glamorous news is that most treatments provide partial relief, work only for certain pain mechanisms, and involve trade-offs such as side effects, cost, limited access, or uncertain long-term benefit. Current U.S. guidance therefore favors individualized, multimodal pain management rather than relying on one heroic pill to save the day.
Medical note: This article is for educational purposes and does not replace diagnosis or treatment from a qualified healthcare professional. Sudden severe pain, chest pain, new weakness, loss of bladder or bowel control, major trauma, or pain accompanied by fever may require urgent medical evaluation.
Why pain is so difficult to treat
Pain is not one disease. Nociceptive pain arises from damaged or inflamed tissue, as in a sprained ankle or osteoarthritis. Neuropathic pain comes from injured or malfunctioning nerves and may feel burning, electric, numb, or shock-like. Nociplastic pain involves altered pain processing without a single injury that fully explains the symptoms, as may occur in fibromyalgia and certain persistent pain syndromes.
A person can have several pain mechanisms at once. This explains why an anti-inflammatory drug may calm an arthritic knee but do almost nothing for diabetic nerve pain. Likewise, a medication that reduces nerve sensitivity cannot automatically repair weak muscles, poor sleep, depression, fear of movement, or an ergonomically disastrous workstation.
Choosing pain treatment is therefore less about finding the “strongest” medicine and more about matching the right tools to the cause, symptoms, risks, and goals of the individual patient.
Current pain treatments and their major deficiencies
1. Acetaminophen and NSAIDs
Acetaminophen is widely used for mild to moderate pain and fever. Nonsteroidal anti-inflammatory drugs, or NSAIDs, include ibuprofen, naproxen, aspirin, celecoxib, and diclofenac. Oral or topical NSAIDs can be useful for arthritis, dental pain, menstrual pain, inflammatory conditions, and musculoskeletal injuries. For acute non-low-back injuries, clinical guidance recommends topical NSAIDs as a first-line option because they can reduce pain with less whole-body exposure.
The deficiency: Familiar does not mean harmless. Excessive acetaminophen can cause severe liver injury, particularly when people accidentally combine multiple cold, flu, sleep, and prescription products containing the same ingredient. NSAIDs may cause stomach ulcers, gastrointestinal bleeding, kidney injury, fluid retention, heart failure, heart attack, or stroke. Risk generally increases with higher doses, longer use, older age, pregnancy, and existing kidney, cardiovascular, or digestive disease. Acetaminophen also performs poorly for some conditions, including certain types of low back pain.
2. Prescription non-opioid medications
Several drugs originally developed for other conditions are now common chronic pain treatments. Duloxetine and certain tricyclic antidepressants may help neuropathic pain, fibromyalgia, osteoarthritis, or chronic low back pain. Gabapentin and pregabalin are used for selected nerve-pain conditions. Muscle relaxants may be prescribed briefly for acute spasms, while topical lidocaine and capsaicin can help localized pain.
The deficiency: Average improvement is often modest. An AHRQ evidence review found that several non-opioid drug classes produced mostly small short-term gains, while intermediate- and long-term outcomes were frequently unavailable. Sedation, dizziness, swelling, nausea, dry mouth, constipation, weight changes, sexual side effects, and withdrawal symptoms can limit treatment. Gabapentinoids may also increase respiratory risk when combined with opioids or other sedating medicines. Finding a suitable drug can resemble speed dating, except everyone is discussing dizziness.
3. Opioid pain medicines
Opioids such as morphine, oxycodone, hydrocodone, and fentanyl remain valuable for severe acute pain, major trauma, surgery, cancer-related pain, palliative care, and selected cases in which safer alternatives are inadequate. They can provide rapid relief and make breathing exercises, movement, sleep, or rehabilitation possible.
The deficiency: Long-term opioid therapy may cause tolerance, constipation, sedation, hormonal disruption, physical dependence, increased pain sensitivity, misuse, addiction, respiratory depression, overdose, and death. Functional benefits remain uncertain for many chronic noncancer pain conditions.
In 2025, the FDA required stronger class-wide labeling about the risks of long-term opioid use. However, abruptly stopping treatment can also cause withdrawal, uncontrolled pain, psychological distress, and other serious harm. Responsible care involves the lowest effective dose, an appropriate duration, regular reassessment, overdose-risk reduction, and shared decisions instead of rigid rules.
4. Physical therapy, exercise, and rehabilitation
Physical therapy, graded strengthening, aerobic exercise, aquatic activity, mobility training, occupational therapy, and weight management can improve pain and function. These approaches address weakness, stiffness, balance problems, deconditioning, and fear of movement. Guidelines for chronic low back pain support exercise, multidisciplinary rehabilitation, tai chi, yoga, motor-control exercise, and other non-drug therapies before escalating medication.
The deficiency: Rehabilitation takes time, repetition, and enough symptom control to participate. Initial sessions may temporarily increase soreness. Success depends on diagnosis, program quality, adherence, work demands, transportation, and the patient’s ability to afford repeated visits. Insurance may cover a bottle of pills more readily than months of supervised movement, which is a peculiar way for a healthcare system to announce that it understands muscles.
5. Cognitive behavioral therapy and mind-body treatment
Cognitive behavioral therapy, acceptance-based therapy, mindfulness, relaxation training, biofeedback, and pain education do not suggest that pain is imaginary. They aim to reduce pain-related fear, catastrophizing, stress reactivity, sleep disruption, and activity avoidance. Acupuncture, yoga, tai chi, massage, and mindfulness may also provide modest benefit for selected chronic pain conditions.
The deficiency: Benefits are generally moderate, research quality varies, and access to trained professionals is uneven. Patients may also reject psychological treatment when it is presented poorly. Explaining that stress and sleep influence pain processing can be helpful. Telling someone that the pain is “all in your head” is scientifically inaccurate and spectacularly unhelpful.
6. Injections, nerve procedures, and surgery
Corticosteroid injections, epidural injections, nerve blocks, radiofrequency ablation, joint injections, and surgery can help when a specific pain generator has been identified. Joint replacement may transform life for someone with advanced osteoarthritis, while decompression surgery can help selected patients with nerve compression.
The deficiency: Many procedures provide temporary rather than permanent relief. Steroid injections may increase blood glucose, weaken tissue with repeated exposure, or cause infection and bleeding. The FDA has warned about rare but serious neurological complications following epidural corticosteroid injections.
Some heavily marketed regenerative treatments also lack convincing evidence. The American College of Rheumatology recommends against platelet-rich plasma and stem-cell injections for hip and knee osteoarthritis because adequate benefit has not been established. Surgery may fail to eliminate pain, produce scar tissue, or replace one limitation with another.
7. Neuromodulation and implanted devices
Spinal cord stimulation and peripheral nerve stimulation use electrical signals to modify pain transmission. They may help carefully selected patients with severe neuropathic pain that has not responded to conservative treatment. A temporary trial is usually completed before permanent implantation.
The deficiency: Neuromodulation is invasive, costly, and not consistently effective for every condition. Leads may move, batteries require management, infections can occur, and some patients lose benefit over time. Medicare coverage guidance treats spinal cord stimulation as a late option after medication, rehabilitation, psychological treatment, and less invasive therapies have been attempted. Patient selection is the difference between sophisticated treatment and very expensive optimism.
8. Cannabis and cannabinoid products
Some patients report that cannabis or cannabinoid products reduce neuropathic symptoms, sleep disruption, or pain-related distress. Short-term research suggests small pain reductions for certain formulations.
The deficiency: Product potency, THC-to-CBD ratios, labeling accuracy, delivery methods, and legal standards vary considerably. Possible harms include dizziness, sedation, anxiety, cognitive impairment, unsafe driving, medication interactions, and cannabis use disorder.
In 2025, the American College of Physicians concluded that, for many people with chronic noncancer pain, known harms may outweigh the small potential benefit. Results from standardized research products may also be difficult to apply to high-potency products sold in dispensaries.
Deficiencies affecting the entire pain-treatment system
Benefits are often smaller than patients expect
Clinical studies report average results. A treatment may help a small group substantially, help many people slightly, and provide no benefit to others. Advertising naturally introduces the delighted group rather than the person who experienced a 12% improvement and mild nausea.
A treatment can still be worthwhile without eliminating pain. A modest reduction may allow someone to sleep, walk farther, return to work, or participate in family life. Measuring function and quality of life is often more useful than pursuing a perfect pain score of zero.
Long-term evidence remains limited
Many trials last only weeks or months, although chronic pain can continue for decades. Short studies may miss tolerance, delayed adverse effects, declining adherence, repeated procedures, and loss of benefit. This evidence gap contributed to updated FDA guidance in 2026 aimed at improving the development and evaluation of non-opioid treatments for chronic pain.
Treatment selection still relies on trial and error
Imaging, blood tests, and nerve studies can identify some causes, but no routine test can reliably predict whether a patient will respond to duloxetine, acupuncture, spinal stimulation, or a particular exercise program. Genetics, pain mechanism, sleep, mental health, expectations, other illnesses, and social conditions all influence outcomes. Precision pain medicine remains more ambition than daily reality.
Recommended treatments may be inaccessible
Multidisciplinary programs can combine medical care, physical rehabilitation, behavioral health, and social support, but many communities do not have them. Rural patients may travel for hours, while low-income patients face copays, transportation problems, limited paid leave, and insurance restrictions. Nonpharmacologic treatments recommended by guidelines are not always fully covered, making the “best” treatment theoretically available but practically fictional.
Undertreatment and overtreatment can coexist
Fear of opioids may leave some patients with severe pain inadequately treated. In other cases, casual opioid escalation creates avoidable risk. Repeated injections may continue despite minimal improvement, while useful rehabilitation is abandoned because progress feels slow. Pain care can swing between excessive caution and excessive intervention without enough continuity in the middle.
New non-opioid treatments: genuine progress with limitations
In 2025, the FDA approved suzetrigine, the first medicine in a new non-opioid class for moderate to severe acute pain in adults. It targets a peripheral sodium-channel pathway before pain signals reach the brain. This represents meaningful progress because it provides another option without acting through classic opioid receptors.
However, suzetrigine is approved for acute pain, not as a universal chronic pain treatment. It can cause adverse effects and has important drug-interaction restrictions. Clinical trials also allowed rescue ibuprofen, suggesting that even innovative medicines may work best within a multimodal plan rather than as standalone miracles.
Future improvements may come from mechanism-specific medicines, safer sodium-channel blockers, biologic therapies, noninvasive neuromodulation, digital rehabilitation, and biomarkers that predict individual response. The greatest breakthrough will not simply be a stronger painkiller. It will be treating pain without sacrificing alertness, mobility, mood, or long-term health.
What effective pain management looks like today
A practical, evidence-informed plan usually includes the following principles:
- Identify likely pain mechanisms and treat reversible causes.
- Set functional goals, such as sleeping six hours, walking to the mailbox, returning to work, or playing with a child.
- Use the least risky effective options first when clinically appropriate.
- Combine therapies that work through different mechanisms instead of endlessly increasing one medication.
- Monitor pain, function, sleep, mood, and adverse effects at planned intervals.
- Stop treatments that offer no meaningful value while avoiding abrupt withdrawal from medicines that require tapering.
This approach is less emotionally satisfying than promising a cure in seven days. It is also much closer to how pain biology and responsible medicine actually work.
Experiences related to current pain treatments and their deficiencies
The following are composite scenarios based on common treatment experiences. They do not describe identifiable patients or personal clinical experiences.
The office worker with recurring low back pain
A 42-year-old office worker develops low back pain after a weekend of heroic furniture moving, an activity rarely endorsed by the lumbar spine. Ibuprofen helps for several days, but the pain returns whenever work becomes busy and exercise disappears. An MRI shows age-related disc changes, which sound alarming but do not clearly identify the source of his symptoms.
Physical therapy improves hip strength and teaches safer lifting, yet six appointments cannot erase years of sitting, poor sleep, and fear of bending. The treatment still succeeds because he returns to walking and carrying groceries, even though his pain never reaches zero. His experience reveals an important deficiency: medicine often defines success as improved function, while patients understandably arrive hoping for complete silence.
The older adult balancing arthritis relief and medication risk
A 69-year-old woman with knee osteoarthritis gets reliable relief from naproxen. Unfortunately, she also has high blood pressure and reduced kidney function. Acetaminophen is easier on her stomach but barely affects the pain. Topical diclofenac helps one knee, although applying it repeatedly is less convenient than taking a pill. A steroid injection provides relief for two months rather than forever.
Her experience demonstrates why “use a non-opioid” is incomplete advice. Non-opioid does not mean risk-free, and a useful therapy may still be insufficient. Her most effective plan combines topical medication, strengthening, weight management, a cane for long outings, and periodic evaluation for joint replacement. No single treatment wins a trophy, but the team performs better than any solo act.
The patient with burning nerve pain
A man with diabetic neuropathy describes his feet as being “on fire and asleep,” a combination that sounds impossible but is familiar to people with nerve pain. Gabapentin reduces the nighttime burning but causes daytime fogginess. Duloxetine improves pain and mood but initially produces nausea. A lidocaine patch helps only a small area. Better diabetes management may prevent additional nerve damage, but it cannot instantly repair nerves already injured.
After several adjustments, he accepts moderate relief because it permits uninterrupted sleep and safer walking. The deficiency is the uncertainty. Clinicians cannot reliably predict the best medication beforehand, and side effects may appear before benefits. Treatment becomes a carefully monitored experiment rather than a prescription followed by applause.
The long-term opioid patient caught between benefit and risk
A patient with several previous spine surgeries has taken an opioid for years. The medicine does not eliminate pain, but it helps with showering, preparing meals, and taking short walks. A new clinician worries about long-term risk and proposes a rapid reduction. The patient hears, “Your pain is not real.” The clinician means, “I do not want this medicine to harm you.” Communication collapses somewhere between those sentences.
A safer plan reviews function, dosage, sleep apnea, other sedating drugs, overdose risk, naloxone access, and non-opioid options. Any taper is gradual, collaborative, and adjusted if function deteriorates. This experience reveals two deficiencies at once: long-term opioid therapy can be dangerous, but poorly managed discontinuation can also be dangerous. Good pain care requires enough humility to recognize both truths without turning the patient into a policy problem.
The shared lesson from these experiences
Patients often cycle through treatments not because clinicians are careless or because their pain is imaginary, but because current therapies are incomplete and individual responses vary. The best outcomes commonly come from combining several modest improvements: less pain, better sleep, stronger muscles, fewer adverse effects, greater confidence, and a realistic plan for flare-ups.
That may sound less exciting than a miracle cure. For someone returning to work, attending a grandchild’s game, cooking dinner independently, or sleeping through the night, it can still be life-changing.
Conclusion
Current pain treatments range from familiar over-the-counter medicines to advanced implants, rehabilitation programs, behavioral therapies, and new non-opioid drugs. Their shared deficiency is not that they are useless. It is that they are incomplete. Most therapies help selected patients, with selected conditions, by a limited amount and at a cost measured in side effects, time, money, inconvenience, or uncertainty.
The future of pain management should focus on safer mechanism-based treatments, stronger long-term research, better access to multidisciplinary care, and tools that predict individual response. Until then, the strongest strategy is not chasing the most powerful intervention. It is building a personalized plan that improves function, protects safety, and treats the person rather than arguing with a number on a pain scale.
